Epstein-Barr virus EBNA1 peptide-MHC complexes (EBNA1 pMHC)

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) peptide-MHC complexes are immunological targets formed by the presentation of EBNA1-derived viral peptides on the surface of infected or malignant cells via Major Histocompatibility Complex (MHC) molecules. EBNA1 is a critical viral protein consistently expressed in all EBV-associated malignancies, such as nasopharyngeal carcinoma, Burkitt lymphoma, and Hodgkin lymphoma, where it maintains the viral episome and promotes cell survival [1.5.2, 1.5.4]. These pMHC complexes are targeted by T-cell receptors (TCRs) and TCR-like antibodies, making them focal points for immunotherapies like TCR-engineered T cells and vaccines [1.2.1, 1.2.2]. However, EBNA1 utilizes a Gly-Ala repeat (GAr) domain to inhibit its own proteasomal processing, resulting in a low density of pMHC complexes on the cell surface and facilitating immune evasion [1.5.1, 1.5.4]. Despite this, specific epitopes like the HLA-A*02:01-restricted FMVFLQTHI and HLA-B*35:01-restricted HPVGEADYFEY have been successfully targeted in preclinical and clinical studies [1.2.1, 1.4.2]. Furthermore, these complexes are implicated in autoimmune conditions like multiple sclerosis, where EBNA1 peptides may trigger cross-reactive immune responses against host proteins such as myelin basic protein [1.5.5]. Therapeutic strategies targeting these complexes aim to overcome the virus's "stealth" mechanism to induce direct lysis or immune-mediated destruction of EBV-positive tumor cells [1.2.2, 1.2.3].

Other names

EBNA1-HLA complexesEBNA1 peptide-HLA complexesEBNA1-MHC class I complexesEBNA1-MHC class II complexesEBNA1-HLA-A*02:01 complexEBNA1-HLA-B*35:01 complex

T-cell receptor-mediated cytotoxicity, Antibody-dependent cellular cytotoxicity (ADCC), Complement-dependent cytotoxicity (CDC), T-cell activation